

Androgen receptors in breast cancer. - Bryan RM - *Cancer* - 1-DEC-1984; 54(11): 2436-40 (From NIH/NLM MEDLINE)

Abstract:

Androgen receptor assays have been performed on 1371 specimens of histologically confirmed primary and recurrent breast cancer. Forty-two patients who had received tamoxifen as treatment for advanced disease were assessed for objective response. Another 42 patients who had received chemotherapy were similarly studied. Patients with androgen receptor-negative tumors had a significantly poorer response rate to hormone therapy than those with receptor-positive tumors (P less than 0.05). This clinical correlation is supported by survival data of 1181 patients with primary breast cancer which showed that patients with androgen receptor-negative tumors had a highly significant trend toward shorter overall survival than those with receptor-positive tumors (P less than 0.001). Androgen receptor data added significantly to the information provided by estrogen receptor data both in terms of response to hormone treatment and survival.

Citation:

Androgen receptors in breast cancer.
Bryan RM - *Cancer* - 1-DEC-1984; 54(11): 2436-40
From NIH/NLM MEDLINE

NLM Citation ID:
6498736 (PubMed ID)

Full Source Title:
Cancer

Publication Type:
Journal Article

Language:
English

Authors:
Bryan RM; Mercer RJ; Bennett RC; Rennie GC; Lie TH; Morgan FJ

Major Subjects:

- Breast Neoplasms / * analysis / pathology / therapy
- Receptors, Androgen / * analysis / drug effects
- Receptors, Steroid / * analysis

Additional Subjects:

- Female
- Follow-Up Studies
- Humans
- Menopause
- Neoplasm Metastasis
- Prognosis
- Receptors, Estrogen / analysis / drug effects
- Tamoxifen / therapeutic use

Chemical Compound Name:
(Receptors, Androgen); (Receptors, Estrogen); (Receptors, Steroid); 10540-29-1(Tamoxifen)

Copyright © 2007 Elsevier Inc. All rights reserved. - www.mdconsult.com

Bookmark URL: /das/journal/view/0/N/6849509?source=MI